Musculoskeletal Tumour Biopsy — Principles & Technique

The Central Principle

The biopsy is the most important and most commonly mishandled step in the management of a musculoskeletal tumour. A technically perfect resection cannot rescue a patient from a badly-placed biopsy that has contaminated tissue planes, an uninvolved compartment, or a neurovascular bundle.

The governing rule is that the biopsy must be performed by, or in direct discussion with, the surgeon who will perform the definitive resection, at the specialist sarcoma / multidisciplinary team (MDT) centre.

Mankin's Evidence — Why the Centre Matters

The landmark studies by Mankin and colleagues remain the cornerstone evidence:

• Mankin et al. (1982) PMID 7130225 — original Musculoskeletal Tumor Society survey of 329 biopsies: troubling rates of error in diagnosis and technique, with complications that adversely affected patient care, occurring far more often when biopsy was done at the referring rather than the treating institution.
• Mankin et al. (1996) PMID 8642021 — repeat study (597 patients from 21 institutions) showed the problem had not improved: the overall diagnostic error rate was 17.8%; a biopsy problem forced a different, often more complex operation in 19.3%; the course/outcome changed (more complex resection, disability, local recurrence or death) in 10.1%; and 18 patients had an unnecessary amputation attributable to the biopsy. Errors, complications and changes in course/outcome were 2 to 12 times greater (p less than 0.001) when the biopsy was done in a referring institution rather than a treatment centre.

The conclusion of both studies: refer the patient with the lesion intact; biopsy at the centre that will treat the patient.

Indications for Biopsy

A biopsy is performed to obtain a tissue diagnosis that will determine definitive treatment, once clinical assessment and staging imaging raise concern for a primary bone or soft-tissue tumour.

When Biopsy is Indicated

• Any soft-tissue mass that is deep to fascia, greater than 5 cm, enlarging, or symptomatic — treat as sarcoma until proven otherwise
• An aggressive or indeterminate bone lesion on imaging (cortical destruction, periosteal reaction, soft-tissue extension, indeterminate matrix)
• Suspected primary bone sarcoma (osteosarcoma, Ewing sarcoma, chondrosarcoma)
• A solitary destructive bone lesion in an adult where metastasis or myeloma is possible but a tissue diagnosis is required (after screening for a known primary)
• Confirmation of metastatic disease where it would change management and the primary is unknown or in doubt

When Biopsy May Be Deferred or Avoided

• Classic benign latent lesions with pathognomonic imaging (non-ossifying fibroma, classic osteochondroma, simple bone cyst, classic enchondroma) — observe; biopsy is not required
• Lesions where the diagnosis is established radiologically by the MDT (e.g. typical osteoid osteoma treated directly)
• A known primary carcinoma with multiple typical bone metastases — biopsy of the most accessible lesion only if it will alter management

Sequence — Biopsy is the LAST Step

The biopsy must follow, not precede, the staging work-up:

1. History, examination, plain radiographs
2. Staging imaging completed first — whole-bone MRI with contrast (local stage, skip lesions), CT chest (pulmonary metastases), bone scan / FDG-PET as indicated
3. MDT discussion of imaging and a definitive surgical plan
4. Biopsy performed last, with the tract chosen to fit the planned resection

Performing the biopsy before staging imaging produces haematoma and oedema that distort the MRI, can over-stage the lesion, and may render the imaging uninterpretable for resection planning.

Why Imaging Comes First

All staging imaging must be complete and reviewed before the biopsy, for three reasons:

1. Avoid distortion — a biopsy creates haematoma, oedema and a needle tract that contaminate the MRI signal and obscure true tumour margins
2. Target the biopsy — contrast MRI and PET identify the viable, enhancing periphery (where representative tissue lies) and the necrotic centre (to avoid)
3. Plan the tract — cross-sectional imaging defines compartmental anatomy and the neurovascular bundle, allowing a safe corridor to be chosen

Staging Imaging

Staging Systems

Enneking (Surgical Staging System — MSTS)

The Enneking system stages musculoskeletal sarcomas by surgical grade, anatomical compartment and metastasis:

• Grade: G1 (low) / G2 (high), based on histological grade
• Site (T): T1 = intracompartmental / T2 = extracompartmental
• Metastasis (M): M0 = none / M1 = present
• Stages: IA (G1 T1), IB (G1 T2), IIA (G2 T1), IIB (G2 T2), III (any M1)

This system directly drives the surgical margin required (intralesional, marginal, wide, radical) and is central to why the biopsy tract must be controlled — the tract is, in effect, a contaminated extension of the tumour.

AJCC (TNM) Staging

The AJCC TNM system grades bone and soft-tissue sarcoma by tumour size and depth (T), nodal involvement (N), metastasis (M) and histological grade (G). It is used alongside Enneking for prognostication and oncological reporting.

Planning the Tract

The tract is planned jointly with the definitive surgeon so that it can be excised en bloc with the specimen:

• Longitudinal orientation, aligned with the planned resection incision
• Shortest direct route from skin to the most representative (viable) part of the tumour
• Single compartment — never cross an uninvolved compartment, joint, or NV interval
• Clear of the neurovascular bundle — image-guidance lets the radiologist choose a corridor that avoids vessels and nerves
• Marked / tattooed so the tract is unmistakably identified and excised at definitive surgery

Choice of Technique

The technique is chosen by the MDT to obtain a representative, diagnostic sample with the least contamination and morbidity. In modern practice image-guided core needle biopsy is the first-line technique for the majority of bone and soft-tissue tumours.

Core Needle Biopsy (First-Line)

• Performed under image guidance (ultrasound for soft tissue, CT for deep bone lesions) so the corridor and target are precisely controlled
• A coaxial system allows multiple cores through a single skin entry — minimising the contaminated tract
• Target the viable enhancing periphery identified on MRI/PET; obtain multiple cores
• Send tissue for histology AND microbiology — infection is the principal mimic of a bone tumour
• Advantages: high accuracy (pooled about 84% across 7,209 lesions; 90-95% in specialist centres), low morbidity, day-case, small excisable tract, lower cost. Accuracy is highest when the biopsy is performed by an experienced musculoskeletal radiologist
• The skin entry point and tract are still chosen by / agreed with the definitive surgeon and marked for later excision

Fine Needle Aspiration (FNA)

• Yields cytology only — no tissue architecture, limited grading and subtyping
• Meta-analysis evidence: highly reliable for the benign-vs-malignant distinction (sensitivity about 96%, specificity about 97%) but only about 76% accurate for a definitive subtype diagnosis
• Useful for confirming recurrence or metastasis when the diagnosis is already known
• Not adequate as the primary diagnostic biopsy of a new suspected sarcoma

Open Incisional Biopsy

Reserved for cases where core biopsy is non-diagnostic or where larger tissue volume is required.

Technique Principles

• Longitudinal incision, directly over the most superficial part of the tumour, in line with and excisable by the definitive resection incision
• Shortest route to the tumour through a single compartment — do NOT raise flaps, do NOT cross compartments
• Take a representative sample of viable peripheral tumour under direct vision; avoid the necrotic centre
• Frozen section to confirm diagnostic lesional tissue is present before closing
• Meticulous haemostasis — any haematoma carries tumour cells along tissue planes and expands the contaminated field
• No drains, or if drainage is unavoidable bring the drain out in line with and immediately adjacent to the incision so the drain track lies within the future resection field
• Close in layers to seal the tumour; avoid wide undermining

Excisional Biopsy

• Appropriate only for small (typically less than 3-5 cm), superficial, clearly benign or low-grade lesions
• Removing the whole lesion as a 'biopsy' of a sarcoma contaminates the entire surgical bed and converts the whole field into a tract requiring much wider re-resection
• Never perform an excisional biopsy on a suspected high-grade or deep sarcoma

Complications of a Poorly-Planned Biopsy

The complications of biopsy are overwhelmingly the consequence of poor planning and technique — and many are catastrophic for the patient's oncological outcome.

The Most Important Pitfalls (Exam Gold)

• Biopsy before referral — the single commonest serious error; refer the lesion intact to the sarcoma centre
• Transverse incision — contaminates the whole limb width; longitudinal only
• Crossing compartments / NV bundles — converts salvage to sacrifice
• Biopsy before staging imaging — distorts the MRI and ruins resection planning
• Excisional biopsy of a sarcoma — turns the whole bed into a contaminated tract
• Failure to send microbiology — infection is the great mimic; always culture as well as biopsy
• Sampling the necrotic centre — non-diagnostic; target viable periphery

Handling the Specimen

• Send fresh tissue promptly to pathology; the specialist sarcoma pathologist may need fresh material for cytogenetics / molecular studies (e.g. translocation studies for Ewing sarcoma and synovial sarcoma)
• Send tissue for histology AND microbiology in every case — infection is the principal differential of a destructive bone lesion
• Frozen section intra-operatively confirms that diagnostic lesional tissue has been obtained before the patient leaves theatre (it does not give the final diagnosis)
• Ensure adequate tissue for immunohistochemistry and molecular testing — multiple cores or a generous incisional sample

Documentation and Marking

• Document and mark the tract (skin tattoo / clear operative note) so the definitive surgeon excises it en bloc with the specimen
• Photograph and record the entry point; a forgotten or undocumented tract may be left behind and act as a focus for recurrence

Multidisciplinary Team (MDT) Review

The biopsy result is interpreted in the specialist sarcoma MDT, where:

• The radiologist, pathologist and surgeon correlate imaging, histology and clinical findings — discordance triggers re-review or re-biopsy
• The definitive plan is set: neoadjuvant chemotherapy (e.g. osteosarcoma, Ewing sarcoma), radiotherapy, and the type and timing of resection
• The margin required is defined (intralesional / marginal / wide / radical per Enneking) and the resection includes the biopsy tract

Radiology–Pathology Discordance

If the histology does not fit the imaging (for example, benign-looking histology from an aggressive-looking lesion), the result is treated as non-diagnostic / sampling error, not reassurance. The MDT re-reviews and the patient is re-biopsied rather than discharged.

Key Take-Home

The biopsy is part of a continuum that begins with referral to the sarcoma centre and ends with en-bloc excision of the tract at definitive surgery. Every decision — sequence, site, orientation, technique, haemostasis, specimen handling, and documentation — is made to protect the option of limb salvage and an accurate diagnosis.